Avalo Therapeutics' Abdakibart shows strong Phase 2 results for hidradenitis suppurativa, advancing to Phase 3 trials

Avalo Therapeutics announced positive Phase 2 results for Abdakibart (AVTX-009) in treating moderate to severe hidradenitis suppurativa (HS). The LOTUS trial met its primary endpoint with response rates over 42% at Week 16, the highest observed in trials of this size, showing significant improvement in key clinical measures. Abdakibart was well tolerated with a favorable safety profile, and Avalo plans to advance the drug into Phase 3 registrational trials. This progress highlights the potential of IL-1β inhibition as a new treatment option for HS patients.